Abbvie Inc (ABBV) is overvalued and AMGEN Inc (AMGN) is slightly overvalued.
Both trade above our estimate of their intrinsic value. AMGN is the closer of the two: -11%, against -148% for ABBV.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 7.1% (average of 3 methods) values the shares at $106.86; the price of $265.21 is 148% above that value, and 83% of that value comes from beyond year five.
Leak Score 57/100 on 8 of 12 signals
Discounting its cash flows at 7.5% (average of 3 methods) values the shares at $369.87; the price of $410.24 is 11% above that value, and 81% of that value comes from beyond year five.
Leak Score 51/100 on 10 of 12 signals
| Metric | ABBV | AMGN |
|---|---|---|
| Verdict | Overvalued | Slightly overvalued |
| Price | $265.21 | $410.24 |
| Intrinsic value | $106.86 | $369.87 |
| Margin of safety | -148% | -11% |
| Leak Score | 57/100 (8/12) | 51/100 (10/12) |
| Market cap | $468.7B | $221.8B |
| Revenue growth, 5 years | 6.0% | 7.8% |
| Operating margin | 34.2% | 33.3% |
| Net margin | 9.7% | 22.9% |
| Return on equity | 15221.8% | 91.5% |
| Debt to equity | — | 4.90 |
| P/E | 75.0x | 25.5x |
| Forward P/E | 16.2x | 16.8x |
| P/B | — | 19.0x |
| Dividend yield | 2.6% | 2.5% |